LAUSR

BACKGROUND Glioblastoma (GBM) is a highly lethal malignancy for which neoangiogenesis serves as a defining hallmark. The anti-VEGF antibody, bevacizumab, has been approved for the treatment of recurrent GBM, but resistance is universal. METHODS We analyzed expression data of GBM patients treated with bevacizumab to discover potential resistance mechanisms. Patient-derived xenografts (PDXs) and cultures were interrogated for effects of phosphofructokinase-1, muscle isoform (PFKM) loss on tumor cell motility, migration, and invasion through genetic and pharmacologic targeting. RESULTS We identified PFKM as a driver of bevacizumab resistance. PFKM functions dichotomize based on subcellular location: Cytosolic PFKM interacted with KIF11, a tubular motor protein, to promote tumor invasion, whereas nuclear PFKM safeguarded genomic stability of tumor cells through interaction with NBS1. Leveraging transcriptional profiles, bupivacaine phenocopied genetic targeting of PFKM and enhanced efficacy of bevacizumab in preclinical GBM models in vivo. CONCLUSION PFKM drives novel molecular pathways in GBM, offering a translational path to a novel therapeutic paradigm.